Andere Sprachen Alzamend Neuro, Inc.

Aktien

A3EYCP

US02262M4078

ALZN

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 30.04.2024			% 5 Tage	% 1. Jan.
0,711 ^USD	+0,14 %		-2,01 %	-20,11 %

25.03.	Alzamend Neuro, Inc. meldet Ergebnis für das dritte Quartal und die neun Monate bis zum 31. Januar 2024	CI
05.01.	Alzamend Neuro, Inc. ernennt Milton C. Ault, III zum Direktor und stellvertretenden Vorsitzenden	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Alzamend Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	25.03.
Alzamend Neuro, Inc. announced that it expects to receive $6 million in funding from Ault Lending, LLC	31.01.
Alzamend Neuro, Inc. Appoints Milton C. Ault, III as a Director and Vice Chairman	05.01.
Alzamend Neuro, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	15.12.
Alzamend Neuro Receives FDA Study May Proceed Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients	12.12.
Alzamend Neuro, Inc. Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients	11.12.
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients	11.12.
Alzamend Neuro Receives FDA Approval to Proceed With Phase 2A Study of AL001 Depression Treatment Candidate	20.11.
Alzamend Neuro Gets FDA Approval for Trial of Depression Treatment	20.11.
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients	20.11.
Alzamend Neuro Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients	20.11.
Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement	17.11.
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement	16.11.
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001	13.11.
Alzamend Neuro, Inc. Submits IND Application for A Phase IIa Clinical Trial in Post-Traumatic Stress Disorder Patients of Next-Generation Lithium Therapeutic Drug Candidate AL001	13.11.
Wall Street Set to Open Higher Monday as Investors Parse Earnings, Await Fed Meeting	30.10.23
Alzamend Neuro Announces Reverse Stock Split	30.10.23
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next-Generation Lithium Therapeutic Drug Candidate AL001	24.10.23
Alzamend Neuro Seeks FDA Nod to Start Trial in Major Depressive Disorder	23.10.23
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001	23.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Alzamend Neuro, Inc.

Aktien

A3EYCP

US02262M4078

ALZN

Andere Sprachen

Filter